As iNKT cells can directly kill CD1d-expressing tumor cells, one can hypothesize that the efficacy of iNKT cell-based antitumor responses can also be improved by increasing CD1d-expression levels on tumor cells as this may facilitate their recognition by iNKT cells. The gene discussed is CD1D; the disease is neoplasm.